NCCN recommends rusfertide across PV risk strata as Category 1, uniquely spanning low- and high-risk disease in the updated myeloproliferative neoplasm guidelines. Clinical positioning targets ...
Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...
Geoffrey Y. Ku, MD discusses two of the most active areas of investigation in the perioperative management of gastric and gastroesophageal junction (GEJ) cancers targeting HER2-positive disease and ...
CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers. T-cell–based immunotherapies have transformed the treatment ...
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings. The 23rd International Myeloma Society ...
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...
Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear ...
Bispecific administration is already routine in independent community oncology, with 91.4% of responding practices delivering therapy and 5.4% planning implementation within 12 months. Office-based ...
David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.
Immune thrombocytopenia (ITP) is a disease that, a generation ago, left oncologists cycling patients through cyclophosphamide, dapsone, and splenectomy with modest results, but no ...
Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design. He noted that most earlier analyses lumped KRAS ...
Overall, tiredness, depression, and poor well-being were the most prevalent moderate-to-severe symptoms across cancer types, reported by 37%, 34%, and 33% of patients, respectively. The median total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results